Dec 26, 2018 by Brian Orelli, PhDHow to Save $650 Million Without Really TryingPfizer and GlaxoSmithKline join forces with their consumer healthcare businesses, creating plenty of synergies.
Dec 26, 2018 by Brian Orelli, PhDWhy ImmunoGen Shot Up 13% TodayThe biotech jumps on no obvious news.
Dec 13, 2018 by Brian Orelli, PhDHere's Why Shares of The Medicines Company Sank 14.5% TodayInvestors aren't happy about the drugmaker's latest capital raise.
Dec 11, 2018 by Brian Orelli, PhDHere's Why Momenta Pharmaceuticals Fell for a Second Straight DayVolatility strikes the biotech.
Dec 11, 2018 by Brian Orelli, PhDHere's Why Corcept Therapeutics Rose 18.6% in NovemberSolid revenue growth and pipeline progress from the biotech fueled the rise.
Dec 7, 2018 by Brian Orelli, PhDHere's Why Momenta Pharmaceuticals Jumped 18% on FridayInvestors are excited about all the capital the biotech raised.
Nov 28, 2018 by Brian Orelli, PhDWhy Marijuana Stock Neptune Wellness Solutions Is Up More Than 30% in 2018The chemical-extraction company is striking deals and increasing capacity.
Nov 28, 2018 by Brian Orelli, PhDVertex Looks to Capture the Rest of Its Multibillion-Dollar MarketNew late-stage clinical trial data should help boost its $3 billion franchise.
Nov 27, 2018 by Brian Orelli, PhDCannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?GW Pharmaceuticals' Epidiolex passes its fourth phase 3 study.
Nov 21, 2018 by Brian Orelli, PhDWhy Marijuana Stock INSYS Therapeutics Is Down 30% in 2018It's been a wild year for the drug company.
Nov 20, 2018 by Brian Orelli, PhDHere's Why LivaNova Dropped TodayThe Centers for Medicare and Medicaid Services wants some more data before covering the company’s depression therapy.
Nov 19, 2018 by Brian Orelli, PhDHere's Why Aimmune Therapeutics Closed Down 11.2% After Publishing Its "Landmark" Clinical TrialBalancing efficacy and safety is hard.
Nov 16, 2018 by Brian Orelli, PhDMomenta Moves OnThe biotech is shifting focus away from biosimilars and toward its pipeline of immune drugs.
Nov 15, 2018 by Brian Orelli, PhDAlnylam Pharmaceuticals Launches OnpattroUnfortunately, predicting the steepness of the launch is going to be tough.
Nov 14, 2018 by Brian Orelli, PhDDiplomat Pharmacy: "It Is a Rebuilding Year for Us."The specialty pharmacy is still getting its feet wet as a pharmacy benefits manager.
Nov 14, 2018 by Brian Orelli, PhDGenomic Health Starts SprintingRecord revenue and profits lead management to increase 2018 guidance.
Nov 12, 2018 by Brian Orelli, PhDBecton, Dickinson Closes Out Its Fiscal Year With a BangNext year's revenue may not be so hot, but earnings should grow nicely as the company captures synergies and pays down debt.
Nov 12, 2018 by Brian Orelli, PhDIonis Pharmaceuticals Collects Royalties -- and Spends It AllWith $2 billion in the bank, the biotech can afford to invest in the future.
Nov 9, 2018 by Brian Orelli, PhDWaiting for bluebird bio to Sing at ASHThe American Society of Hematology meeting will be a big event for the biotech.
Nov 9, 2018 by Brian Orelli, PhDImmunoGen Waits to Leap "Forward"Critical data from the Forward I trial is due out in the first half of next year.
